DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6® Cell Line Proteins

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Beleggingsadvies 10/02/2009 16:12
DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6® cell line located in the European Union.

Karen King, president of DSM Biologics notes, "The growing number of PER.C6® licensees requires that we expand the possibilities for our licensees to obtain services like cell line generation. We are confident that Bioceros' excellent experience and service level will provide our European licensees additional options to move their PER.C6® programs forward successfully."

Bram Bout, CEO of Bioceros added "We are honored to achieve the distinction of being the first pre-approved Europe-based cell line generation partner using the PER.C6® cell line. The PER.C6® technology is recognized throughout our industry as providing important advantages compared to other platforms, including its well developed technology, which allow for short manufacturing timelines and exceptionally high productivity levels with off the shelf available culture media. The selection of Bioceros as a preferred Vendor by DSM and Crucell underscores the high quality of the services that we offer to our customers".

The PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6® human cell line and DSM's proprietary XD(TM) technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.




Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL